AXL targeting restores PD-1 blockade sensitivity of <i>STK11/LKB1</i> mutant NSCLC through expansion of TCF1<sup>+</sup> CD8 T cells.

Cell Rep Med · 2022 · PMC9040166 · PMID 35492873

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Combination therapy showed a trend of enrichment of clonally expanded and exhausted effector CD8 T cells in the TME.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.